NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund.
Company Details
- Employees
- 22
- Founded
- -
- Address
- Babraham Research Campus, Room 1020,united Kingdom
- Phone
- +44 (0)1223 804250
- in****@****ore.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- neophore.com
- Keywords
- Biotechnology, Drug Discovery, Small Molecule Therapeutics, Oncology, Immuno-oncology, Cancer, Genetics, Translational Medicine.
- HQ
- Cambridge, Cambridgeshire
Neophore Ltd Questions
Neophore Ltd's helpline number is +44 (0)1223 804250
Neophore Ltd's website is neophore.com
Neophore Ltd's LinkedIn profile is https://uk.linkedin.com/company/neophore-ltd
Neophore Ltd has
22 employees.
View email and phone details for 22
employees at Neophore Ltd.
Neophore Ltd's industry is
Biotechnology Research
Neophore Ltd's top competitors are
Resalis Therapeutics,
Heqet Therapeutics,
Labgenius Therapeutics,
Iama Therapeutics,
Alkemist Bio,
Invizius,
Kither Biotech,
Angelini Ventures,
Sibylla Biotech,
Claris Ventures.
Neophore Ltd's support email address is info@neophore.com
Neophore Ltd's categories are Biotechnology Research
Neophore Ltd's founding year is 2017
